RNA Stock Price, Avidity Biosciences Inc Quote, Chart

Market Summary

USD29.51+0.79

Market Closed

2.75%

RNA Alerts

2 major insider sales recently.

RNA Stock Price

View Fullscreen

RNA RSI Chart

RNA Valuation

Market Cap

2.8B

Price/Earnings (Trailing)

-12.34

Price/Sales (Trailing)

104.49

Price/Free Cashflow

-19.63

RNA Price/Sales (Trailing)

RNA Profitability

Return on Equity

-27.52%

Return on Assets

-24.03%

Free Cashflow Yield

-5.1%

RNA Fundamentals

RNA Revenue

Revenue (TTM)

27.0M

Rev. Growth (Yr)

58.67%

Rev. Growth (Qtr)

-76.19%

RNA Earnings

Earnings (TTM)

-228.7M

Earnings Growth (Yr)

-31.42%

Earnings Growth (Qtr)

-13.92%

Breaking Down RNA Revenue

Last 7 days

13.7%

Last 30 days

25.3%

Last 90 days

108.1%

Trailing 12 Months

176.0%

How does RNA drawdown profile look like?

RNA Financial Health

Current Ratio

12.47

RNA Investor Care

Shares Dilution (1Y)

35.04%

Diluted EPS (TTM)

-2.96

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	27.0M	0	0	0
2023	5.4M	10.6M	10.9M	25.7M
2022	7.8M	6.8M	5.9M	5.0M
2021	8.1M	9.2M	9.6M	8.7M
2020	3.7M	5.0M	6.1M	6.8M
2019	0	1.0M	1.7M	2.3M
2018	0	0	0	379.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Avidity Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 07, 2024	boyce sarah	acquired	34,720	1.24	28,000	president and ceo
May 07, 2024	boyce sarah	sold	-715,050	25.5375	-28,000	president and ceo
Apr 19, 2024	levin arthur a	acquired	6,200	1.24	5,000	-
Apr 19, 2024	levin arthur a	sold	-114,123	22.8246	-5,000	-
Apr 03, 2024	levin arthur a	sold	-542,214	27.1107	-20,000	-
Apr 02, 2024	boyce sarah	acquired	34,720	1.24	28,000	president and ceo
Apr 02, 2024	boyce sarah	sold	-734,919	26.2471	-28,000	president and ceo
Mar 19, 2024	levin arthur a	sold	-119,848	23.9695	-5,000	-
Mar 19, 2024	levin arthur a	acquired	6,200	1.24	5,000	-
Mar 13, 2024	maclean michael f	acquired	352,800	8.82	40,000	chief financial officer

Which funds bought or sold RNA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	JANE STREET GROUP, LLC	added	59.3	2,220,240	2,856,040	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	added	10.19	1,238,720	1,826,570	-%
May 16, 2024	ALETHEA CAPITAL MANAGEMENT, LLC	reduced	-10.99	11,678,400	19,413,000	15.77%
May 15, 2024	Oracle Alpha Inc.	reduced	-19.07	150,805	268,419	0.48%
May 15, 2024	DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)	sold off	-100	-169,307	-	-%
May 15, 2024	BARCLAYS PLC	reduced	-37.44	1,371,000	3,163,000	-%
May 15, 2024	GOLDMAN SACHS GROUP INC	added	45.71	9,949,460	13,149,900	-%
May 15, 2024	Corton Capital Inc.	reduced	-15.99	368,005	636,826	0.23%
May 15, 2024	Bridgefront Capital, LLC	new	-	293,097	293,097	0.22%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	unchanged	-	54,483	84,421	0.01%

Are Funds Buying or Selling RNA?

Are funds buying RNA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own RNA

No. of Funds

RNA Alerts

2 major insider sales recently.

Unveiling Avidity Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 06, 2024	ra capital management, l.p.	5.1%	4,895,959	SC 13G
Mar 11, 2024	price t rowe associates inc /md/	12.1%	9,656,852	SC 13G/A
Mar 01, 2024	rtw investments, lp	9.99%	9,659,809	SC 13D/A
Feb 14, 2024	price t rowe associates inc /md/	9.3%	6,917,910	SC 13G/A
Feb 14, 2024	ra capital management, l.p.	3.3%	2,454,533	SC 13G/A
Feb 13, 2024	vanguard group inc	5.46%	4,043,179	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 02, 2024	cowen financial products llc	7.6%	5,628,103	SC 13G/A
Jan 25, 2024	blackrock inc.	8.8%	6,496,593	SC 13G/A
Jan 24, 2024	rtw investments, lp	8.4%	6,701,489	SC 13D/A

Recent SEC filings of Avidity Biosciences Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	3	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 15, 2024	8-K	Current Report
May 15, 2024	DEFA14A	DEFA14A
May 14, 2024	144	Notice of Insider Sale Intent
May 09, 2024	10-Q	Quarterly Report
May 09, 2024	8-K	Current Report
May 09, 2024	S-3ASR	S-3ASR
May 07, 2024	4	Insider Trading

Peers (Alternatives to Avidity Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Avidity Biosciences Inc News

Latest updates

Avidity Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Revenue	-76.2%	3,543	14,878	2,818	5,771	2,233	87.00	2,482	611	1,795	1,979	2,163	2,607	2,704	2,142	1,746	1,541	1,358	1,445	650	224	-
Operating Expenses	17.1%	80,730	68,936	61,443	54,950	59,829	55,994	47,411	48,477	36,255	40,399	31,443	28,974	26,561	18,435	13,212	11,909	7,508	7,492	5,856	4,129	-
S&GA Expenses	-100.0%	-	16,119	13,729	12,278	12,064	10,384	10,094	8,688	8,567	7,431	6,612	6,268	5,884	4,816	3,757	2,925	1,964	1,847	757	1,596	-
R&D Expenses	26.5%	66,832	52,817	47,714	42,672	47,765	45,610	37,317	39,789	27,688	32,968	24,831	22,706	20,677	13,619	9,455	8,984	5,544	5,645	5,099	2,533	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	131	78.00	4,338	1,462	1,215	-
Net Income	-13.9%	-68,855	-60,443	-52,358	-47,025	-52,394	-50,471	-43,599	-45,690	-34,235	-38,538	-29,274	-26,353	-23,844	-16,275	-11,439	-10,556	-6,085	-10,401	-6,668	-5,116	-
Net Income Margin	-2.5%	-8.47*	-8.26*	-18.54*	-18.30*	-35.50*	-34.97*	-27.45*	-21.63*	-16.55*	-13.58*	-9.96*	-8.47*	-	-	-	-	-	-	-	-	-
Free Cashflow	-555.9%	-71,295	15,638	-37,714	-50,429	-50,787	-40,039	-31,852	-36,868	-30,332	-27,922	-21,582	-28,843	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																	(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Assets	51.4%	951	629	573	611	614	639	431	421	421	428	426	291	315	334	346	355	97.00
Current Assets	52.9%	934	611	555	595	597	623	414	404	405	411	422	287	312	332	344	354	96.00
Cash Equivalents	154.9%	472	185	86.00	154	119	340	144	125	140	321	410	276	301	322	341	352	95.00
Net PPE	3.3%	9.00	8.00	8.00	8.00	8.00	6.00	6.00	6.00	5.00	5.00	3.00	3.00	2.00	1.00	1.00	1.00	1.00
Liabilities	-5.6%	121	128	56.00	52.00	55.00	61.00	54.00	46.00	45.00	46.00	31.00	26.00	29.00	28.00	26.00	25.00	28.00
Current Liabilities	-7.1%	75.00	81.00	49.00	45.00	48.00	52.00	43.00	34.00	31.00	30.00	22.00	16.00	18.00	15.00	14.00	12.00	10.00
Shareholder's Equity	65.9%	831	501	517	559	559	578	377	374	376	381	395	264	286	306	320	330	-
Retained Earnings	-12.1%	-639	-570	-510	-458	-410	-358	-308	-264	-218	-184	-146	-116	-90.38	-66.54	-50.26	-38.83	-22.18
Additional Paid-In Capital	37.3%	1,471	1,071	1,030	1,020	971	939	689	642	597	566	541	381	376	373	370	369	-43.17
Accumulated Depreciation	12.3%	6.00	5.00	-	-	-	3.00	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	20.6%	96.00	79.00	74.00	74.00	71.00	70.00	53.00	50.00	48.00	41.00	39.00	38.00	-	-	-	-	-
Float	-	-	-	-	811	-	-	-	739	-	-	-	798	-	-	-	887	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Cashflow From Operations	-526.5%	-70,380	16,501	-36,791	-49,807	-48,967	-39,189	-31,959	-35,546	-29,574	-26,215	-20,782	-28,135	-19,681	-13,073	-9,113	-7,791	-7,140	-5,019	-5,885	-	-
Share Based Compensation	4.7%	10,306	9,845	9,820	9,453	9,104	7,307	7,086	6,508	6,238	4,516	4,550	4,289	3,701	1,878	1,296	687	449	351	22.00	-	-
Cashflow From Investing	-164.2%	-32,747	51,040	-31,479	46,049	-195,680	-7,768	10,932	-17,644	-175,475	-84,064	-800	2,872	-525	-6,930	-845	-	-10.00	-91.00	-14.00	-	-
Cashflow From Financing	1121.2%	389,445	31,891	40.00	38,972	22,961	243,654	39,620	38,784	24,113	20,714	155,172	413	17.00	450	-1,346	271,610	1,323	71,824	-712	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

RNA Income Statement

2024-03-31

Condensed Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Collaboration revenue	$ 3,543	$ 2,233
Operating expenses:
Research and development	66,832	47,765
General and administrative	13,898	12,064
Total operating expenses	80,730	59,829
Loss from operations	(77,187)	(57,596)
Other income (expense):
Interest income	8,433	5,516
Other expense	(101)	(314)
Total other income	8,332	5,202
Net loss	$ (68,855)	$ (52,394)
Net loss per share, basic (in dollars per share)	$ (0.79)	$ (0.74)
Net loss per share, diluted (in dollars per share)	$ (0.79)	$ (0.74)
Weighted-average shares outstanding, basic (in shares)	87,212	70,433
Weighted-average shares outstanding, diluted (in shares)	87,212	70,433
Other comprehensive income (loss):
Net unrealized gains (losses) on marketable securities	$ (589)	$ 1,169
Comprehensive loss	$ (69,444)	$ (51,225)

RNA Balance Sheet

2024-03-31

Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 471,400	$ 185,082
Marketable securities	444,473	410,269
Prepaid and other assets	18,601	15,956
Total current assets	934,474	611,307
Property and equipment, net	8,655	8,381
Restricted cash	295	295
Right-of-use assets	7,625	8,271
Other assets	425	301
Total assets	951,474	628,555
Current liabilities:
Accounts payable and accrued liabilities	37,330	34,341
Accrued compensation	7,796	14,335
Lease liabilities, current portion	3,726	3,639
Deferred revenue, current portion	26,103	28,365
Total current liabilities	74,955	80,680
Lease liabilities, net of current portion	5,421	6,213
Deferred revenue, net of current portion	40,199	40,898
Total liabilities	120,575	127,791
Commitments and contingencies (Note 7)
Stockholders’ equity:
Common stock, $0.0001 par value; authorized shares – 400,000; issued and outstanding shares – 95,594 and 79,275 at March 31, 2024 and December 31, 2023, respectively	10	8
Additional paid-in capital	1,470,972	1,071,395
Accumulated other comprehensive income (loss)	(464)	125
Accumulated deficit	(639,619)	(570,764)
Total stockholders’ equity	830,899	500,764
Total liabilities and stockholders’ equity	$ 951,474	$ 628,555

About Avidity Biosciences Inc

Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

CEO	Ms. Sarah Boyce
WEBSITE	aviditybiosciences.com
INDUSTRY	Biotechnology
EMPLOYEES	186

Avidity Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Avidity Biosciences Inc? What does RNA stand for in stocks?

RNA is the stock ticker symbol of Avidity Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Avidity Biosciences Inc (RNA)?

As of Fri May 17 2024, market cap of Avidity Biosciences Inc is 2.82 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of RNA stock?

You can check RNA's fair value in chart for subscribers.

What is the fair value of RNA stock?

You can check RNA's fair value in chart for subscribers. The fair value of Avidity Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Avidity Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for RNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Avidity Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether RNA is over valued or under valued. Whether Avidity Biosciences Inc is cheap or expensive depends on the assumptions which impact Avidity Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RNA.

What is Avidity Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, RNA's PE ratio (Price to Earnings) is -12.34 and Price to Sales (PS) ratio is 104.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RNA PE ratio will change depending on the future growth rate expectations of investors.